183 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
strategy to leverage the company’s proven expertise in developing mast cell-targeted therapies to address large medical needs in allergy and inflammation … . The company plans to host additional educational webcasts highlighting the evolving science around Blueprint’s portfolio strategy in the future. Watch
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
or future approved drugs or drug candidates in treating patients; and the company’s strategy, goals, business plans and focus. The words “aim,” “may
8-K
EX-99.1
robk9mhnqk 7s712xn
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
EX-99.1
3r744v 35j5
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.2
oad93u8ag
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.1
1xxdd
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.2
qg78qj71ae yz2y
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
zf2varmlf7d jykjolx
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
b9r 5dyze
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
EX-99.1
jf16m
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am
8-K
EX-10.1
oymres 72iug18hglk
27 Dec 22
Departure of Directors or Certain Officers
4:27pm